Technical Analysis for ESPR - Esperion Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| 50 DMA Resistance | Bearish | 5.50% | |
| Bollinger Band Squeeze | Range Contraction | 5.50% | |
| 50 DMA Resistance | Bearish | 3.14% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 3.14% | |
| Bollinger Band Squeeze | Range Contraction | 3.14% | |
| BB Squeeze + Upper Band Touch | Range Contraction | 3.14% | |
| Up 3 Days in a Row | Strength | 3.14% | |
| Upper Bollinger Band Touch | Strength | 3.14% |
| Alert | Time |
|---|---|
| Rose Above 50 DMA | about 17 hours ago |
| Possible Inside Day | about 18 hours ago |
| 50 DMA Resistance | about 21 hours ago |
| 60 Minute Opening Range Breakout | about 21 hours ago |
| 10 DMA Support | about 22 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/07/2024
Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of therapies for the treatment of patients with low-density lipoprotein cholesterol and other cardiometabolic risk factors. Its products include ETC-1002, an oral molecule therapy that is in Phase IIa clinical trials to treat lipid and carbohydrate metabolic pathways; ESP41091, which is in pre-clinical trials for type 2 diabetes and obesity treatment; and 4WF, a synthetic therapy that is in pre-clinical trials to reverse the deleterious effects of atherosclerosis. The company is based in Plymouth, Michigan.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Diabetes Obesity Lipid Cardiology Cholesterol Lipoprotein Gabaa Receptor Positive Allosteric Modulators Low Density Lipoprotein Atherosclerosis Niacin
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Diabetes Obesity Lipid Cardiology Cholesterol Lipoprotein Gabaa Receptor Positive Allosteric Modulators Low Density Lipoprotein Atherosclerosis Niacin
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.4 |
| 52 Week Low | 0.7 |
| Average Volume | 7,750,613 |
| 200-Day Moving Average | 1.83 |
| 50-Day Moving Average | 2.28 |
| 20-Day Moving Average | 2.08 |
| 10-Day Moving Average | 2.17 |
| Average True Range | 0.21 |
| RSI (14) | 54.13 |
| ADX | 18.84 |
| +DI | 23.20 |
| -DI | 15.39 |
| Chandelier Exit (Long, 3 ATRs) | 1.91 |
| Chandelier Exit (Short, 3 ATRs) | 2.33 |
| Upper Bollinger Bands | 2.33 |
| Lower Bollinger Band | 1.82 |
| Percent B (%b) | 0.93 |
| BandWidth | 24.95 |
| MACD Line | -0.02 |
| MACD Signal Line | -0.06 |
| MACD Histogram | 0.0402 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.56 | ||||
| Resistance 3 (R3) | 2.54 | 2.43 | 2.52 | ||
| Resistance 2 (R2) | 2.43 | 2.36 | 2.44 | 2.50 | |
| Resistance 1 (R1) | 2.36 | 2.32 | 2.40 | 2.39 | 2.49 |
| Pivot Point | 2.25 | 2.25 | 2.27 | 2.26 | 2.25 |
| Support 1 (S1) | 2.19 | 2.18 | 2.22 | 2.21 | 2.11 |
| Support 2 (S2) | 2.08 | 2.14 | 2.09 | 2.10 | |
| Support 3 (S3) | 2.01 | 2.08 | 2.08 | ||
| Support 4 (S4) | 2.04 |
